Institute Chinese Materia Medica China Academy of Chinese Medical Sciences, Beijing, People's Republic of China.
Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Int J Nanomedicine. 2024 Sep 23;19:9843-9870. doi: 10.2147/IJN.S459510. eCollection 2024.
Evodiamine (EVO) is a tryptamine indole alkaloid and the main active ingredient in . In recent years, the antitumor, cardioprotective, anti-inflammatory, and anti-Alzheimer's disease effects of EVO have been reported. EVO exerts antitumor effects by inhibiting tumor cell activity and proliferation, blocking the cell cycle, promoting apoptosis and autophagy, and inhibiting the formation of the tumor microvasculature. However, EVO has poor solubility and low bioavailability. Several derivatives with high antitumor activity have been discovered through the structural optimization of EVO, and new drug delivery systems have been developed to improve the solubility and bioavailability of EVO. Current research found that EVO could have toxic effects, such as hepatotoxicity, nephrotoxicity, and cardiac toxicity. This article reviews the pharmacological activity, derivatives, drug delivery systems, toxicity, and pharmacokinetics of EVO and provides research ideas and references for its further in-depth development and clinical applications.
吴茱萸碱(EVO)是一种色胺吲哚类生物碱,也是 的主要活性成分。近年来,有报道称 EVO 具有抗肿瘤、心脏保护、抗炎和抗阿尔茨海默病的作用。EVO 通过抑制肿瘤细胞的活性和增殖、阻断细胞周期、促进细胞凋亡和自噬以及抑制肿瘤微血管的形成来发挥抗肿瘤作用。然而,EVO 的溶解度低,生物利用度也较低。通过对 EVO 的结构优化,发现了几种具有高抗肿瘤活性的衍生物,并开发了新的药物传递系统来提高 EVO 的溶解度和生物利用度。目前的研究发现,EVO 可能具有毒性作用,如肝毒性、肾毒性和心脏毒性。本文综述了 EVO 的药理学活性、衍生物、药物传递系统、毒性和药代动力学,为其进一步深入开发和临床应用提供了研究思路和参考。
Int J Nanomedicine. 2024
Molecules. 2009-5-18
Ecotoxicol Environ Saf. 2024-8
Adv Exp Med Biol. 2016
Front Pharmacol. 2025-7-25
Nat Rev Clin Oncol. 2023-5
Front Pharmacol. 2022-6-20